Ampligen® (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotherapy in patients with metastatic and locally advanced pancreatic cancer (LAPC)
New patient data provide further validation for advancing the development of Ampligen for the treatment of late-stage pancreatic cancer
New data were recently presented by Professor C.H.J. van Eijck, MD, PhD of Erasmus Medical Center at the 5th Dutch Multidisciplinary Gastrointestinal Oncology Congress held in Ermelo, Netherlands
